GSK’s Tesaro wins latest round in AstraZeneca dispute
Tesaro, a subsidiary of UK pharma major GSK (LSE: GSK), has come up on top in the latest stage of its legal battle with Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) regarding the ovarian cancer drug Zejula (niraparib).
The UK’s Court of Appeal ruled in favor of Tesaro in a row over whether royalties were applicable to all Zejula sales, or restricted to the sales within the scope of patents licensed to the company by AstraZeneca, according to a report from Commercial Dispute Resolution.
In April of last year, the High Court had ruled in favor of AstraZeneca, finding that Tesaro was obligated to pay the Cambridge-based company in each country where at least one licensed patent subsists.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze